Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG.

Burke MJ, Salzer WL, Devidas M, Dai Y, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP.

Haematologica. 2019 May;104(5):986-992. doi: 10.3324/haematol.2018.204545. Epub 2018 Dec 13.

2.

Peritoneal dialysis-related peritonitis: challenges and solutions.

Salzer WL.

Int J Nephrol Renovasc Dis. 2018 Jun 11;11:173-186. doi: 10.2147/IJNRD.S123618. eCollection 2018. Review.

3.

Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.

Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP.

Cancer. 2018 Mar 15;124(6):1150-1159. doi: 10.1002/cncr.31099. Epub 2017 Dec 19.

4.

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.

Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, Chen IM, Valentine M, Liu Y, Li Y, Shao Y, Easton J, Payne-Turner D, Gu Z, Tran TH, Nguyen JV, Devidas M, Dai Y, Heerema NA, Carroll AJ 3rd, Raetz EA, Borowitz MJ, Wood BL, Angiolillo AL, Burke MJ, Salzer WL, Zweidler-McKay PA, Rabin KR, Carroll WL, Zhang J, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP.

Blood. 2017 Jun 22;129(25):3352-3361. doi: 10.1182/blood-2016-12-758979. Epub 2017 Apr 13.

5.

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.

Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA Jr, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG.

Nat Commun. 2016 Nov 8;7:13331. doi: 10.1038/ncomms13331.

6.

A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.

Rodriguez V, Kairalla J, Salzer WL, Raetz EA, Loh ML, Carroll AJ, Heerema NA, Wood BL, Borowitz MJ, Burke MJ, Asselin BL, Devidas M, Winick NJ, Carroll WL, Hunger SP, Dreyer ZE.

J Pediatr Hematol Oncol. 2016 Aug;38(6):409-17. doi: 10.1097/MPH.0000000000000589.

7.

Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232.

Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, Mattano LA Jr, Cole C, Eicher A, Haugan M, Sorenson M, Heerema NA, Carroll AA, Gastier-Foster JM, Borowitz MJ, Wood BL, Willman CL, Winick NJ, Hunger SP, Carroll WL.

J Clin Oncol. 2016 Jul 10;34(20):2380-8. doi: 10.1200/JCO.2015.62.4544. Epub 2016 Apr 25.

8.

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.

Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer WL, Nachman JB, Carroll AJ, Heerema NA, Gastier-Foster JM, Willman CL, Dai Y, Winick NJ, Hunger SP, Carroll WL, Larsen E.

Blood. 2015 Aug 20;126(8):964-71. doi: 10.1182/blood-2015-03-633685. Epub 2015 Jun 29.

9.

Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.

Salzer WL, Jones TL, Devidas M, Dreyer ZE, Gore L, Winick NJ, Sung L, Raetz E, Loh ML, Wang CY, De Lorenzo P, Valsecchi MG, Pieters R, Carroll WL, Hunger SP, Hilden JM, Brown P.

Pediatr Blood Cancer. 2015 Mar;62(3):414-8. doi: 10.1002/pbc.25311. Epub 2014 Nov 18.

10.

Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).

Dreyer ZE, Hilden JM, Jones TL, Devidas M, Winick NJ, Willman CL, Harvey RC, Chen IM, Behm FG, Pullen J, Wood BL, Carroll AJ, Heerema NA, Felix CA, Robinson B, Reaman GH, Salzer WL, Hunger SP, Carroll WL, Camitta BM.

Pediatr Blood Cancer. 2015 Mar;62(3):419-26. doi: 10.1002/pbc.25322. Epub 2014 Nov 14.

11.

Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.

Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP.

Ann N Y Acad Sci. 2014 Nov;1329:81-92. doi: 10.1111/nyas.12496. Epub 2014 Aug 5. Review.

12.

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP.

Blood. 2013 Jul 25;122(4):507-14. doi: 10.1182/blood-2013-01-480822. Epub 2013 Jun 5.

13.

Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407.

Salzer WL, Jones TL, Devidas M, Hilden JM, Winick N, Hunger S, Carroll WL, Camitta B, Dreyer ZE.

Pediatr Blood Cancer. 2012 Nov;59(5):834-9. doi: 10.1002/pbc.24132. Epub 2012 Apr 5.

14.

Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Salzer WL, Winick NJ, Wacker P, Lu X, Devidas M, Shuster JJ, Mahoney DH, Lauer SJ, Camitta BM.

J Pediatr Hematol Oncol. 2012 Jan;34(1):e1-7. doi: 10.1097/MPH.0b013e31820ee239.

15.

Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia.

Raetz EA, Salzer WL.

J Pediatr Hematol Oncol. 2010 Oct;32(7):554-63. doi: 10.1097/MPH.0b013e3181e6f003. Review.

PMID:
20724951
16.

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.

Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, Camitta BA.

Leukemia. 2010 Feb;24(2):355-70. doi: 10.1038/leu.2009.261. Epub 2009 Dec 17.

17.

Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Salzer WL, Devidas M, Shuster JJ, Wang C, Chauvenet A, Asselin BL, Camitta BM, Kurtzberg J; Children's Oncology Group.

J Pediatr Hematol Oncol. 2007 Jun;29(6):369-75.

PMID:
17551397
18.

Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.

Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA, McGlennen R, Smith FO, Woods WG, Salzer WL, Johnstone HS, Dreyer Z, Reaman GH; Children's Oncology Group.

Blood. 2006 Jul 15;108(2):441-51. Epub 2006 Mar 23.

19.

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.

Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P, Balis FM.

J Clin Oncol. 2006 Jan 20;24(3):507-16.

PMID:
16421428
20.

Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.

Trotman RL, Williamson JC, Shoemaker DM, Salzer WL.

Clin Infect Dis. 2005 Oct 15;41(8):1159-66. Epub 2005 Sep 12. Review.

PMID:
16163635
21.

Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid.

Widemann BC, Sung E, Anderson L, Salzer WL, Balis FM, Monitjo KS, McCully C, Hawkins M, Adamson PC.

J Pharmacol Exp Ther. 2000 Sep;294(3):894-901.

PMID:
10945838
22.

Gonococcal arthritis in an era of increasing penicillin resistance. Presentations and outcomes in 41 recent cases (1985-1991).

Wise CM, Morris CR, Wasilauskas BL, Salzer WL.

Arch Intern Med. 1994 Dec 12-26;154(23):2690-5.

PMID:
7993152
24.

Biochemical, physiological and clinical aspects of endotoxemia.

Olson NC, Salzer WL, McCall CE.

Mol Aspects Med. 1988;10(6):511-629. Review. No abstract available.

PMID:
3076605
25.

Disseminated gonococcal infection caused by chromosomally mediated penicillin-resistant organisms.

Strader KW, Wise CM, Wasilauskas BL, Salzer WL.

Ann Intern Med. 1986 Mar;104(3):365-6. No abstract available.

PMID:
3080937
26.

Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain.

Surles JR, Wykle RL, O'Flaherty JT, Salzer WL, Thomas MJ, Snyder F, Piantadosi C.

J Med Chem. 1985 Jan;28(1):73-8.

PMID:
4038418
27.

Diacylglycerol activates protein kinase C and modulates oxidative metabolism in human neutrophils.

McCall CE, McPhail LC, Salzer WL, Schmitt JD, Nasrallah V, Kim J, Wykle RL, O'Flaherty JT, Bass DA.

Trans Assoc Am Physicians. 1985;98:253-68. No abstract available.

PMID:
3022443
28.

Platelet-activating factor and analogues: comparative studies with human neutrophils and rabbit platelets.

O'Flaherty JT, Salzer WL, Cousart S, McCall CE, Piantadosi C, Surles JR, Hammett MJ, Wykle RL.

Res Commun Chem Pathol Pharmacol. 1983 Feb;39(2):291-309.

PMID:
6844746
29.

Platelet activating factor (1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine). Activity of analogs lacking oxygen at the 2-position.

Wykle RL, Surles JR, Piantadosi C, Salzer WL, O'Flaherty JT.

FEBS Lett. 1982 May 3;141(1):29-32. No abstract available.

30.

Supplemental Content

Loading ...
Support Center